14:20:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.


2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-09-03 08:50:00

Scandinavian ChemoTech AB (publ) ("ChemoTech" or "the Company") hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 18 before transaction costs. The capital injection enables an upshift of the Company's long-term strategy.

The Board of ChemoTech has, with the support of authorisation from the Annual General Meeting on May 24, 2021, decided on a directed new issue of 874,211 Series B shares at a subscription price of SEK 20.59 per share. The subscription price corresponds to a discount of approximately 15 percent in relation to the average volume-weighted price (VWAP) for the share on the Nasdaq First North Growth Market over the past 3 trading days.

It is the Board's assessment that the subscription price is market-based and reflects prevailing market conditions and demand. The reason why the share issue has been carried out, and the reasons for the deviation from the shareholders' preferential rights is that it provides the company with working capital in a sufficiently time- and cost-effective manner and take advantage of future opportunities to bring in long-term stable owners and finance the Company's growth strategy.

Investors in the directed new share issue consist of three investors are as follows:

Investors Amount shares Amount in SEK
Kattson i Sverige AB 24 284 500 007,56
Nyenburgh Holding B.V 728 509 15 000 000,31
Mangold Fondkommisison AB 121 418 2 499 996,62

The largest subscriber in this issue is the Dutch investment company Nyenburgh Holding B.V, with whom we have had an active dialogue since May. In ChemoTech's financial strategy, the Company has sought and now attracted new capital from both new and international players, who are long-term and share ChemoTech's commitment and vision. For more information, please visit Nyenburgh Holding B.V.'s website: https://www.nyenburgh.com

"After an intensive spring with, among other things, a successful CE marking, it has now been possible to complete a directed new share issue. This Share issue creates the conditions for an increased focus on commercialisation and clinical validation of both existing and new indications, such as pancreatic cancer." - says Mohan Frick CEO

The Share issue issues a dilution of approximately 9.19 percent of the number of shares and votes in the Company calculated according to the Share issue. Following the registration of the Private Placement with the Swedish Companies Registration Office, the total number of outstanding shares will increase by 874,211, from 8,633,427 to 9,507,638. The share capital will increase by SEK 437,105.50, from approximately SEK 4,316,713.50 to approx. 4,753,819.00.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-09-2021 08:50 CET.